Laurel Grove Capital LLC grew its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 39.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,241 shares of the company’s stock after buying an additional 4,891 shares during the quarter. Laurel Grove Capital LLC’s holdings in Henry Schein were worth $1,205,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HSIC. Bridge Creek Capital Management LLC grew its stake in Henry Schein by 79.6% in the fourth quarter. Bridge Creek Capital Management LLC now owns 28,567 shares of the company’s stock worth $1,996,000 after purchasing an additional 12,660 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Henry Schein by 51.8% in the fourth quarter. State of Alaska Department of Revenue now owns 46,418 shares of the company’s stock worth $3,241,000 after purchasing an additional 15,840 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Henry Schein by 2.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 581,967 shares of the company’s stock worth $40,668,000 after purchasing an additional 16,205 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in Henry Schein by 47.6% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 3,100 shares of the company’s stock worth $217,000 after purchasing an additional 1,000 shares in the last quarter. Finally, National Pension Service grew its stake in Henry Schein by 8.3% in the fourth quarter. National Pension Service now owns 176,655 shares of the company’s stock worth $12,345,000 after purchasing an additional 13,612 shares in the last quarter. 91.75% of the stock is currently owned by hedge funds and other institutional investors.

In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the sale, the director now owns 48,172 shares in the company, valued at $3,408,650.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.19% of the stock is owned by corporate insiders.

Shares of Henry Schein, Inc. (NASDAQ HSIC) opened at $76.41 on Tuesday. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $11,922.26, a price-to-earnings ratio of 22.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.00. Henry Schein, Inc. has a twelve month low of $65.28 and a twelve month high of $93.50.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.84 EPS. equities analysts forecast that Henry Schein, Inc. will post 3.6 EPS for the current year.

Several research analysts recently issued reports on the company. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Royal Bank of Canada dropped their price objective on Henry Schein from $91.00 to $82.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 7th. Jefferies Group reissued a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a research note on Friday, October 20th. Stephens assumed coverage on Henry Schein in a research note on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 price objective on the stock. Finally, Morgan Stanley cut Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price objective on the stock. in a research note on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $84.23.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/23/laurel-grove-capital-llc-has-1-21-million-stake-in-henry-schein-inc-hsic.html.

Henry Schein Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.